The ALS Association is inviting researchers to submit proposals for its Managing ALS Research Program and The 2019 Lawrence and Isabel Barnett Drug Development Program. Applicants are encouraged to apply no later than October 7, 2019.
The Managing ALS Research Program will fund applied research that advances the quality of ALS management in the United States, including assistive technology; interventions that support activities of daily living; epidemiological studies; the quality and affordability of services and treatments; and documenting and alleviating the burdens of ALS. This program will award grants up to $200,000 for 2 years.
Click here for details on the Managing ALS Research Program.
The aim of The Lawrence and Isabel Barnett Drug Development Program is to develop new therapies for ALS including pharmacological treatments, biologics, and gene therapy. Eligible topics include proof-of-concept testing of lead molecules in animal models of ALS; determination of target engagement, pharmacokinetics, pharmacodynamics, and preclinical toxicology/safety; and development of pharmacologic agents through adsorption, distribution, metabolism, excretion, and toxicity phase. Clinical trials will not be supported by this program. This program will award grants up to $500,000 for 2 years.
Click here for details on The Lawrence and Isabel Barnett Drug Development Program.
Proposals for both programs will likely require resources beyond those available at a single organization. Therefore, applications are open to investigators participating in synergistic collaborations. The ALS Association strongly encourages partnerships in all areas of research. Click here to read a blog about collaboration by Neil Thakur, Ph.D., The ALS Association Executive Vice President, Mission Strategy.